Search
Estradiol dienanthate
go.drugbank.com/drugs/DB13955ApprovedVet approvedWithdrawnEster pro-drugs of estradiol are therefore considered to be bioidentical forms of estrogen [T84]. … Following absorption, the esters are cleaved, resulting in the release of endogenous estradiol, or 17β-estradiol.
Equine Botulinum Neurotoxin G Immune FAB2
go.drugbank.com/drugs/DB13899ApprovedEquine Botulinum Neurotoxin G Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype G. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes G in adults and pediatric patients.
Synonyms: Botulinum Neurotoxin G immune FAB2 (equine), BOTULINUM NEUROTOXIN G IMMUNE FAB2, EQUINEEquine Botulinum Neurotoxin D Immune FAB2
go.drugbank.com/drugs/DB13902ApprovedEquine Botulinum Neurotoxin D Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype D. … It is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes D in adults and pediatric patients.
Artesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigational[L890] Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin].[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099] … Artesunate is indicated for the initial treatment of severe malaria.[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria.
Products: ARTESUN POWDER FOR INJECTION 60 MGQuinine
go.drugbank.com/drugs/DB00468ApprovedInvestigationalAn alkaloid derived from the bark of the cinchona tree. … The mechanisms of its antimalarial effects are not well understood.
Products: QUININE SULPHATE TABLETS 300 mgVamorolone
go.drugbank.com/drugs/DB15114ApprovedInvestigational[L48671,L48676] In December 2023, it was approved in the EU for the treatment of patients ≥4 years of age.[L49505] … [L48676] Corticosteroid therapy is the current standard of care for DMD despite relatively high rates of adverse effects.
Deutivacaftor
go.drugbank.com/drugs/DB15141ApprovedInvestigationalIt is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis. … [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive
Udenafil
go.drugbank.com/drugs/DB06267ApprovedIt is not yet approved for use in the U.S., E.U., or Canada.
Categories: combinations of sulfonamidesProducts: ZYDENA 100 MG, ZYDENA 100 MG FILM TABLET, 2 ADETRanibizumab
go.drugbank.com/drugs/DB01270ApprovedInvestigationalBYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada. … The development of ranibizumab first began after [bevacizumab], another anti-VEGF anticancer drug, was discovered to inhibit neovascularization and used in the off-label treatment of neovascular age-related
Products: LUCENTIS® 10 MG /ML SOLUCION INYECTABLE, LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGELeucine
go.drugbank.com/drugs/DB00149ApprovedInvestigationalNutraceuticalAn essential branched-chain amino acid important for hemoglobin formation.
Mixtures: Numeta G 13 % E Emulsion zur Infusion, Numeta G 16 % E Emulsion zur Infusion